The lutetium-177 market growth in 2026 is experiencing strong growth as cancer prevalence increases and demand rises for targeted therapies. Pharmaceutical companies are also expanding research and development activities and introducing Lu-177-based products for different cancer applications.
According to Fortune Business Insights, the global lutetium-177 market size was valued at USD 2.73 billion in 2025. The market is projected to grow from USD 3.43 billion in 2026 to USD 14.70 billion by 2034, exhibiting a CAGR of 19.95% during the forecast period. North America dominated the lutetium-177 market with an 80.95% share in 2025. Lutetium-177 (Lu-177) is a radioactive isotope used in nuclear medicine and targeted radionuclide therapy, particularly for neuroendocrine tumors and certain types of prostate cancer. Its ability to deliver targeted radiation while minimizing damage to surrounding healthy tissues makes it an important option in oncology.
Market Drivers & Restraints:
The increasing prevalence of cancer is a major factor supporting lutetium-177 market growth. Prostate cancer and neuroendocrine tumors are among the key applications driving demand. Lu-177 therapies can bind to specific receptors on cancer cells, including prostate-specific membrane antigen in prostate cancer, allowing radiation to be delivered directly to tumors while reducing exposure to surrounding healthy tissues. The growing demand for targeted cancer treatment is therefore supporting adoption.
However, the high cost associated with Lu-177 treatment remains a major restraint, particularly in lower-middle-income countries. The expenses related to radiopharmaceutical production, specialized equipment, and trained personnel contribute to the overall treatment cost. Limited radiotherapy infrastructure, inadequate reimbursement policies, and the absence of standardized regulatory frameworks for nuclear medicine also restrict wider adoption.
Production complexities represent another challenge. Manufacturing high-purity Lu-177 requires specialized facilities and materials, while stringent regulatory requirements for radioactive materials can make production and distribution more complex. These factors may limit manufacturers' ability to meet increasing demand efficiently.
Market Competitive Landscape:
The global lutetium-177 market is consolidated, with a limited number of major players accounting for a significant market presence. Novartis AG held a significant portion of the market in 2024, supported by its robust product portfolio, regulatory approvals for Lu-177 products, and strong geographic presence. Other companies are strengthening their positions through research activities, pipeline development, collaborations, supply agreements, and product-related initiatives.
𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗜𝗻 𝗧𝗵𝗲 Market
- Novartis AG (Switzerland)
- Telix Pharmaceuticals Limited (Australia)
- Ariceum Therapeutics (Germany)
- Radiopharm Theranostics Limited (Australia)
- Lantheus Holdings, Inc. (U.S.)
- Y-mAbs Therapeutics, Inc. (U.S.)
- GLYTHERIX (Australia)
- Curium (France)
Market Segments:
By Drug (LUTATHERA {lutetium Lu 177 dotatate}, PLUVICTO {lutetium Lu 177 vipivotide tetraxetan}, and Others)
By Age Group (Adults and Pediatrics)
By Application (Neuroendocrine Tumor, Prostate Cancer, and Others)
By End-User (Hospitals, Specialty Clinics, and Others)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/lutetium-177-market-112740
Market Regional Insights:
North America dominated the global lutetium-177 market in 2025, generating USD 2.21 billion and accounting for an 80.95% market share. The regional market is projected to reach USD 2.73 billion in 2026. Rising cancer prevalence, advanced healthcare facilities, strong radiation therapy infrastructure, and robust reimbursement policies for cancer care are supporting regional growth. The U.S. accounted for a significant portion of the regional market, supported by advanced healthcare facilities and radiopharmaceutical manufacturing capabilities.
Europe represented USD 0.34 billion in 2025, accounting for 12.36% of the global market, and is projected to reach USD 0.45 billion in 2026. Increasing cancer cases, demand for targeted therapies, advanced healthcare facilities, and reimbursement policies are supporting market development in the region.
Asia Pacific generated USD 0.13 billion in 2025, representing 4.78% of the global market, and is expected to reach USD 0.17 billion in 2026. The region is projected to be the fastest-growing market during the forecast period. Increasing cancer cases associated with the rising geriatric population and lifestyle changes, along with research and development activities by key players, are supporting growth.
Future Market Scope:
The future outlook for the lutetium-177 market remains strong as the use of targeted radiopharmaceutical therapies expands across cancer applications. Fortune Business Insights identifies increasing clinical trials targeting new application areas as a significant opportunity. Pharmaceutical companies are expanding research and development capabilities to develop Lu-177 therapies for advanced cancers, while regulatory approvals for new candidates may support broader adoption.
Combination therapy is also emerging as a potential market trend. Integrating Lu-177 with other therapeutic modalities, including immunotherapy and chemotherapy, may improve treatment efficacy and help address resistance. Companies are increasingly collaborating to develop advanced therapeutic approaches. Growing awareness of targeted therapies and increasing applications of Lutetium-177 are expected to favor product adoption over the forecast period.
Explore Japan’s Market Opportunities - Latest -Lutetium-177 Market- Insights